Looking at this filing, I need to extract the substantive financial and operational content. The filing text provided is primarily the cover page, table of contents, and forward-looking statements boilerplate. Let me assess the substantive disclosure content carefully. The filing identifies COMPASS Pathways plc, trading as CMPS on the Nasdaq Global Select Market, with 138,476,822 shares outstanding as of July 30, 2026, for the quarterly period ended June 30, 2026. The forward-looking statements section does contain substantive program disclosures about COMP360 psilocybin treatment, TRD Phase 3 program, NDA rolling submission, PTSD Phase 2b/3 trial, DEA rescheduling, and cash runway references. These forward-looking items represent the company's own disclosed plans and programs. I have enough substantive content to write a compliant article.

COMPASS Pathways plc filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 5, 2026, covering the three-month period ended June 30, 2026.

Key Highlights

  • Shares outstanding: The registrant reported 138,476,822 shares of common stock outstanding as of July 30, 2026.
  • Filer status: COMPASS Pathways is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • Lead program: The company's primary investigational asset is COMP360 psilocybin treatment, with an active Phase 3 program targeting treatment-resistant depression (TRD), the filing disclosed.
  • Regulatory milestone: According to the filing, COMP360 has received rolling review status and a National Priority Voucher, which the company stated may accelerate FDA review of its planned new drug application for TRD.
  • DEA rescheduling required: The filing noted that COMP360 contains Schedule I controlled substances and must be rescheduled by the U.S. Drug Enforcement Administration before any commercialization in the U.S.
  • Additional pipeline: The registrant also disclosed an ongoing Phase 2b/3 clinical trial in post-traumatic stress disorder (PTSD) as part of its development portfolio.

COMPASS Pathways COMP360 Program Status and Regulatory Pathway

COMPASS Pathways plc, incorporated in England and Wales and headquartered at 33 Broadwick Street, London, trades on the Nasdaq Global Select Market under the symbol CMPS. The company's quarterly report for the period ended June 30, 2026, describes its operations as centered on the development of COMP360 psilocybin treatment, with treatment-resistant depression as the primary indication.

According to the filing, COMPASS Pathways has two Phase 3 trials underway for TRD and has disclosed preliminary results to date from those studies. The registrant stated it is pursuing a rolling submission of a new drug application with the FDA for COMP360 in TRD. The filing noted that the FDA has granted rolling review and awarded a National Priority Voucher for COMP360 in TRD, which the company described as potentially accelerating the FDA's review timeline. All statements about timing and outcomes of regulatory processes are presented in the filing as forward-looking statements subject to the company's cautionary language.

The filing also described the requirement that the U.S. Drug Enforcement Administration, and individual states, must reschedule COMP360 before commercialization can proceed in the U.S., given that the treatment contains Schedule I controlled substances. In addition to TRD, the company reported an active Phase 2b/3 clinical trial in PTSD, with ongoing discussions with the FDA regarding trial design for that program. The registrant also referenced its estimates of cash resources and expected cash runway as forward-looking considerations, without providing specific figures in the portions of the filing made available.

What Was Disclosed

COMPASS Pathways plc submitted its Form 10-Q for the quarter ended June 30, 2026, reporting 138,476,822 shares outstanding, ongoing Phase 3 TRD and Phase 2b/3 PTSD trials for COMP360 psilocybin treatment, and a planned NDA rolling submission supported by an FDA National Priority Voucher and rolling review designation.